The only case studies on cordis.com are four 2022 template pages, still live and in the sitemap, telling one coronary case built around the GuideLiner catheter, a Promus stent and a Sprinter balloon, none of them Cordis products, under "Lorem Ipsum Header" subheadings and a Lorem ipsum disclaimer. SELUTION SLR has just become the first and only sirolimus drug-eluting balloon approved in the U.S. for ISR, and interventional cardiologists evaluating it will look for exactly this: real cases.
First action
Unpublish the four Case Study Example pages and redirect them to the SELUTION SLR page.
How to measure it
Information requests from case pages
- Now
- –
- Target
- 40 a month
- By
- 90 days
Steps
Remove placeholders
Unpublish, drop from the sitemap, redirect.
Specialist II Digital Marketing 1 day
Pick cases
Three to five ISR cases with images and consent.
Manager, Medical Education 2 weeks
Write them
Presentation, technique, result, follow-up.
Senior Manager, Product Marketing 2 weeks
Review
On-label and claims check.
Regulatory Affairs and Legal 1 week
Publish
Case library template linked from the product page.
Specialist II Digital Marketing 2 days
Use in the field
Cases in rep follow-up emails.
Territory Manager ongoing
Measure
Visits and requests per case.
Specialist II Digital Marketing monthly
Why it works
Take the four placeholders down today (remove from the sitemap and redirect to the SELUTION page). Then publish a case library built on the same URL pattern: three to five ISR cases from SELUTION4ISR investigators or early U.S. users, each with presentation, angiography, device sizing, result and follow-up, reviewed by Medical Affairs and Regulatory as on-label. Link it from the SELUTION product page, the TCT page and the field team's follow-up emails.
Physicians adopt a new device class through peer cases. The placeholders currently show competitors' devices under the Cordis brand; real cases turn the same pages into launch proof for the product marketing and medical education teams being hired now.
Ready to use
ChecklistSELUTION case page template
[ ] Patient presentation (de-identified) [ ] Lesion and prior stent history [ ] Device and sizing [ ] Technique notes [ ] Result and follow-up [ ] Physician quote and disclosure [ ] Indication and important safety information [ ] Link to trial data and IFU [ ] Request Additional Information form
Risks and how to handle them
Case selection looks promotional
Medical Affairs chooses cases; include balanced outcomes and safety information.
Image consent
Use de-identified images with documented consent.
Evidence
- Your websiteFour pages titled "Case Study Example 1" to "Case Study Example 4" (published 2022) are live and listed in the sitemap under /na/case-studies/. Each tells the same coronary case "made possible by the GuideLiner catheter", naming other devices Cordis does not sell (a Promus stent, a Sprinter balloon), with "Lorem Ipsum Header" subheadings, a Lorem ipsum disclaimer and a "Back to Radianz Home" link. They are the only case studies on the site.Source
- Your websiteFDA approval news (September 21, 2026): SELUTION SLR DEB is approved for coronary in-stent restenosis (ISR) and is "the first and only sirolimus drug-eluting balloon approved in the United States". SELUTION4ISR enrolled more than 400 patients at 48 sites; "nearly 1 million" PCIs a year in the U.S., about 10% for ISR; SELUTION4DeNovo (960 patients, small vessels) has completed enrollment. Cordis introduced the first sirolimus drug-eluting stent in the U.S. in 2003.Source
- HiringSenior Manager, Product Marketing (remote, posted October 1, 2026): translate "approved clinical evidence into clear, differentiated commercial positioning", create "evidence summaries, data-driven messaging tools, congress materials, field-facing resources", lead symposia and congress programs, and support the field with "objection handling, and competitive response materials".Source
- HiringMedical education hiring: a Manager, Medical Education (posted October 16, 2026) to run "workshops, proctoring pathways, virtual learning, symposia" and track programs with "defined KPIs"; a Senior Manager, Medical Education to "Create the universal framework for program analytics", "Develop end to end strategy supporting Medical Education digital marketing" and build faculty "for future technologies (IVL, Carotid, Peripheral) from pre-launch to post market".Source